Bristol-Myers Squibb Co.
Stock Symbol: BMY
345 Park Ave
Bristol-Myers Squibb Co. Industry:
Bristol-Myers Squibb Co. Description:
Bristol-Myers Squibb Company, through its divisions and subsidiaries, is a producer and distributor of consumer medicines, pharmaceuticals, nutritionals, medical devices and beauty care products. For the fiscal year ended 12/31/01, net sales rose 7% to $19.42 billion. Net income from continuing operations fell 38% to $2.53 billion. Results reflect increased volume and selling prices of pharmaceutical products, offset by the inclusion of a $2.74 billion acquired R&D charge.
Bristol-Myers Squibb Co. Financial Summary:
Bristol-Myers Squibb Company is a global producer and distributor of a variety of pharmaceuticals and related healthcare products. For the six months ended 06/30/05, net sales fell less than 1% to $9.4M. Net income from cont. ops. rose 3% to $1.5M. Revenues reflect lower sales from the pharmaceuticals division. Net income reflects decreased litigation charges, lower provision for restructuring and decreased provision for income taxes.
Bristol-Myers Squibb Co. Business Summary:
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare-related products. The Company operates in three segments: Pharmaceuticals, Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international (excluding Japan) consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. The Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines (North America and Japan) businesses. In December 2004, the Company committed to a plan to sell its Oncology Therapeutics Network (OTN) business and entered into a definitive agreement with One Equity Partners LLC. In January 2005, the Company announced its intent to divest its United States and Canadian Consumer Medicines business.